Viruses 2010, 2(8), 1621-1634; doi:10.3390/v2081621

Cyclophilin Inhibitors as a Novel HCV Therapy

Received: 17 June 2010; in revised form: 23 July 2010 / Accepted: 4 August 2010 / Published: 5 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: A critical role of Cyclophilins, mostly Cyclophilin A (CyPA), in the replication of HCV is supported by a growing body of in vitro and in vivo evidence. CyPA probably interacts directly with nonstructural protein 5A to exert its effect, through its peptidyl-prolyl isomerase activity, on maintaining the proper structure and function of the HCV replicase. The major proline substrates are located in domain II of NS5A, centered around a “DY” dipeptide motif that regulates CyPA dependence and CsA resistance. Importantly, Cyclosporine A derivatives that lack immunosuppressive function efficiently block the CyPA-NS5A interaction and inhibit HCV in cell culture, an animal model, and human trials. Given the high genetic barrier to development of resistance and the distinctness of their mechanism from that of either the current standard of care or any specifically targeted antiviral therapy for HCV (STAT-C), CyP inhibitors hold promise as a novel class of anti-HCV therapy.
Keywords: Cyclophilins; Cyclosporine A; immunosuppression; nonstructural protein 5A/5B; HCV replication
PDF Full-text Download PDF Full-Text [140 KB, uploaded 5 August 2010 17:26 CEST]

Export to BibTeX |

MDPI and ACS Style

Tang, H. Cyclophilin Inhibitors as a Novel HCV Therapy. Viruses 2010, 2, 1621-1634.

AMA Style

Tang H. Cyclophilin Inhibitors as a Novel HCV Therapy. Viruses. 2010; 2(8):1621-1634.

Chicago/Turabian Style

Tang, Hengli. 2010. "Cyclophilin Inhibitors as a Novel HCV Therapy." Viruses 2, no. 8: 1621-1634.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert